Some researchers theorize that IL-17 may contribute to COVID-19 pathogenesis and inflammation in the lungs [6], and as such, it is important to investigate the impact of taking IL-17 inhibitors on the risk of infection and severity of COVID-19 disease. Here, IL17A is linked to infection.